NCT04817241View on ClinicalTrials.gov

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

October 25, 2025

Study Completion Date

October 25, 2025

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Cytarabine

Given IV

DRUG

Daunorubicin

Given IV

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (7)

10461

Montefiore Medical Center-Einstein Campus, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

14263

Roswell Park Cancer Institute, Buffalo

22908

University of Virginia Cancer Center, Charlottesville

35233

University of Alabama at Birmingham Cancer Center, Birmingham

37232

Vanderbilt University/Ingram Cancer Center, Nashville

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH